ZURICH, Switzerland, March 15 /PRNewswire/ -- Prionics AG, the world leader in testing procedures for bovine spongiform encephalopathy (BSE), today issued the following statement in response to the announcement by the U.S. Department of Agriculture (USDA) regarding additional BSE surveillance measures: "Prionics praises the approach taken by the USDA and its decision to bolster the surveillance, detection and response program," said Dr. Markus Moser, CEO of Prionics. "The USDA's additional actions will further strengthen U.S. prevention systems and the confidence of both consumers and customers around the world." "Prionics offers both rapid test technologies, the ELISA and the Western Blot, but recommends the Western Blot for the current surveillance system in the U.S. because of its flawless record of returning no false positive results," added Moser. "False positives cause a loss in consumer confidence and can have a detrimental economic impact, particularly in BSE free countries like the United States." Prionics(R)-Check WESTERN is considered by many animal health authorities internationally to be the most accurate rapid-test procedure for BSE in the world. In fact, in 2003, the USDA stated a preference for Western Blot technology particularly in BSE free countries. Prionics(R)-Check WESTERN rapid BSE test has been used in more than 18 million of the 30 million BSE tests conducted worldwide between 2001 and 2003 -- without returning a false positive result. About Prionics AG Prionics AG has the largest number of scientists in the industry focused on BSE and works closely with a network of prion and neurological experts around the world. Prionics' surveillance concept has led to the establishment of official EU-wide BSE screening programs in 2001, and Prionics(R)-Check WESTERN is the preferred test in these programs. Prionics AG, based in Zurich, Switzerland, is an ISO 9001 certified company with production facilities in Switzerland and the U.S. and currently employs 100 people. For more information about Prionics, please visit www.prionics.ch.
SOURCE Prionics AG